
Chemical Structure
ONX 0914 [960374-59-8]

AG-CR1-3674
Overview
- SupplierAdipoGen Life Sciences
- Product NameONX 0914
- Delivery Days Customer10
- CAS Number960374-59-8
- CertificationResearch Use Only
- Estimated Purity>98%
- Hazard InformationWarning
- Molecular FormulaC31H40N4O7
- Molecular Weight580.7
- Scientific DescriptionChemical. CAS: 960374-59-8. Formula: C31H40N4O7. MW: 580.7. Synthetic. Potent and selective 20S immunoproteasome inhibitor. Targets the beta5i subunit [LMP7] of the 20S immunoproteasome (IC50=73nM) and with minimal crossreactivity to the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=1.04microM). Potent anti-inflammatory and anticancer agent. Inhibits production of pro-inflammatory cytokines and can induce apoptosis in vitro. Inhibits presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo, which consequently blocks production of interleukin-23 (IL-23) by activated monocytes and IFN-gamma and IL-2 by T cells. Can also inhibit IL-17-producing T cells under TH17-polarizing conditions in vitro and reduce TH1 and TH17 cell differentiation in vivo. Shown to attenuate disease progression in several experimental models of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus, as well as in some hematologic malignancies and other cancer types. - Potent and selective 20S immunoproteasome inhibitor. Targets the beta5i subunit [LMP7] of the 20S immunoproteasome (IC50=73nM) and with minimal cross-reactivity to the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=1.04microM). Potent anti-inflammatory and anticancer agent. Inhibits production of pro-inflammatory cytokines and can induce apoptosis in vitro. Inhibits presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo, which consequently blocks production of interleukin-23 (IL-23) by activated monocytes and IFN-gamma and IL-2 by T cells. Can also inhibit IL-17-producing T cells under TH17-polarizing conditions in vitro and reduce TH1 and TH17 cell differentiation in vivo. Shown to attenuate disease progression in several experimental models of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus, as well as in some hematologic malignancies and other cancer types.
- SMILESO=C(N[C@@H](C)C(N[C@@H](CC1=CC=C(OC)C=C1)C(N[C@@H](CC2=CC=CC=C2)C([C@]3(C)OC3)=O)=O)=O)CN4CCOCC4
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200